Human carotid plaque phosphatidylcholine specifically interacts with paraoxonase 1, increases its activity, and enhances its uptake by macrophage at the expense of its binding to HDL

Free Radical Biology and Medicine

Volumn 76, Issue 1, 2014, Pages 14-24

  Cohen, Elad ^a,b,c   Aviram, Michael ^c   Khatib, Soliman ^a   Artoul, Fadi ^a   Rabin, Asaf ^c   Mannheim, Dalit ^d   Karmeli, Ron ^d   Salamon, Tal ^e   Vaya, Jacob ^a  

^a MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^b TEL HAI COLLEGE   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

^d CARMEL MEDICAL CENTER   (Israel)

^e Rebecca Sieff Government Hospital   (Israel)

Author keywords

Atherosclerosisl; Human carotid plaque; Macrophage; Paraoxonase 1 (PON1); Phosphatidylcholine

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ENZYME; GLUCONOLACTONASE; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; FATTY ACID; PON1 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ARTICLE; BLOOD COMPONENT; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; CHEMISTRY; HUMAN; HUMAN CELL; INCUBATION TIME; MACROPHAGE; MOLECULAR DOCKING; MUTANT; NONHUMAN; PROTEIN PROTEIN INTERACTION; WILD TYPE; ATHEROSCLEROTIC PLAQUE; GENETICS; LIQUID CHROMATOGRAPHY; METABOLISM; MUTATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROTEIN CONFORMATION; TANDEM MASS SPECTROMETRY;

ARYLDIALKYLPHOSPHATASE; CAROTID ARTERIES; CHROMATOGRAPHY, LIQUID; FATTY ACIDS, NONESTERIFIED; HUMANS; LIPOPROTEINS, HDL; MACROPHAGES; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR DOCKING SIMULATION; MUTATION; PHOSPHATIDYLCHOLINES; PLAQUE, ATHEROSCLEROTIC; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; TANDEM MASS SPECTROMETRY;

EID: 84907963382     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2014.07.036     Document Type: Article

References (42)

1. Ross, R. Cell biology of atherosclerosis. Annu. Rev. Physiol. 57:791-804; 1995.
2. Kleemann, R.; Zadelaar, S.; Kooistra, T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc. Res. 79:360-376; 2008.
3. Hermus, L.; Lefrandt, J. D.; Tio, R. A.; Breek, J.-C.; Zeebregts, C. J. Carotid plaque formation and serum biomarkers. Atherosclerosis 213:21-29; 2010.
4. Miller, N. E.; La Ville, A.; Crook, D. Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit. Nature 314:109-111; 1985.
5. Kontush, A.; Chantepie, S.; Chapman, M. J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23:1881-1888; 2003.
6. Barter, P. J.; Puranik, R.; Rye, K. A. New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr. Cardiol. Rep 9:493-498; 2007.
7. Nofer, J.; Giet, M.; Van, D. e. r.; Tölle, M.; Wolinska, I.; Lipinski, K. V. W.; Baba, H. A.; et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P 113(3):569-581; 2004.
8. Yuhanna, I. S.; Zhu, Y.; Cox, B. E.; Hahner, L. D.; Osborne-Lawrence, S.; Lu, P.; et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7:853-857; 2001.
9. Camont, L.; Chapman, M. J.; Kontush, A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol. Med. 17: 594-603; 2011.
10. Navab, M.; Yu, R.; Gharavi, N.; Huang, W.; Ezra, N.; Lotfizadeh, A.; et al. High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr. Atheroscler. Rep. 9:244-248; 2007.
11. Krauss, R. M. Lipoprotein subfractions and cardiovascular disease risk. Curr. Opin. Lipidol. 21:305-311; 2010.
12. Aviram, M.; Hardak, E.; Vaya, J.; Mahmood, S.; Milo, S.; Billicke, S.; et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101:2510-2517; 2000.
13. Shih, D. M.; Welch, C.; Lusis, A. J.; Lusis, A. New insights into atherosclerosis from studies with mouse models. Mol. Med. Today 1(8):364-372; 1995.
14. Shih, D. M.; Xia, Y.; Wang, X.; Miller, E.; Castellani, L. W.; Subbanagounder, G.; et al. Combined serum paraoxonase knockout / apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis 275:17527-17535; 2000.
15. Rozenberg, O. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 34:774-784; 2003.
16. Mackness, B.; Quarck, R.; Verreth, W.; Mackness, M.; Holvoet, P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 26:1545-1550; 2006.
17. Rozenberg, O.; Shih, D. M.; Aviram, M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 181: 9-18; 2005.
18. Cece, H.; Yazgan, P.; Karakas, E.; Karakas, O.; Demirkol, A.; Toru, I.; et al. Carotid intima-media thickness and paraoxonase activity in patients with ankylosing spondylitis. Clin. Invest. Med. 34:E225; 2011.
19. Fuhrman, B.; Volkova, N.; Aviram, M. Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. Atherosclerosis 161:307-316; 2002.
20. Rozenberg, O.; Shih, D. M.; Aviram, M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler. Thromb. Vasc. Biol. 23:461-467; 2003.
21. Rosenblat, M.; Vaya, J.; Shih, D.; Aviram, M. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 179:69-77; 2005.
22. Bergmeier, C.; Siekmeier, R.; Gross, W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin. Chem. 50:2309-2315; 2004.
23. Rosenblat, M.; Karry, R.; Aviram, M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 187: 74-81; 2006.
24. Aviram, M.; Rosenblat, M.; Billecke, S.; Erogul, J.; Sorenson, R.; Bisgaier, C. L.; Newton, R. S., LDB. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidant 26:892-904; 1999.
25. Jarvik, G. P.; Rozek, L. S.; Brophy, V. H.; Hatsukami, T. S.; Richter, R. J.; Schellenberg, G. D.; et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler. Thromb. Vasc. Biol. 20:2441-2447; 2000.
26. Cohen, E.; Aviram, M.; Khatib, S.; Rabin, A.; Mannheim, D.; Karmeli, R.; et al. Increased levels of human carotid lesion linoleic acid hydroperoxide in symptomatic and asymptomatic patients is inversely correlated with serum HDL and paraoxonase 1 activity. J. Lipids 2012:762560; 2012.
27. Tavori, H.; Aviram, M.; Khatib, S.; Musa, R.; Mannheim, D.; Karmeli, R.; et al. Human carotid lesion linoleic acid hydroperoxide inhibits paraoxonase 1 (PON1) activity via reaction with PON1 free sulfhydryl cysteine 284. Free Radic. Biol. Med. 50:148-156; 2011.
28. Tavori, H.; Aviram, M.; Khatib, S.; Musa, R.; Mannheim, D.; Karmeli, R.; et al. Paraoxonase 1 protects macrophages from atherogenicity of a specific triglyceride isolated from human carotid lesion. Free Radic. Biol. Med. 51:234-242; 2011.
29. Tavori, H.; Aviram, M.; Khatib, S.; Musa, R.; Nitecki, S.; Hoffman, A.; et al. Human carotid atherosclerotic plaque increases oxidative state of macrophages and low-density lipoproteins, whereas paraoxonase 1 (PON1) decreases such atherogenic effects. Free Radic. Biol. Med. 46:607-615; 2009.
30. Khersonsky, O.; Tawfik, D. S. Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases. Chembiochem 7:49-53; 2006.
31. Harel, M.; Aharoni, A.; Gaidukov, L.; Brumshtein, B.; Khersonsky, O.; Meged, R.; et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11: 412-419; 2004.
32. Gaidukov, L.; Tawfik, D. S. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 44:11843-11854; 2005.
33. Gan, K. N.; Smolen, A.; Eckerson, H. W. LDB. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19(1):100-106; 1990.
34. Aviram, M. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem. Med. 30:111-118; 1983.
35. Deakin, S. P.; Bioletto, S.; Bochaton-Piallat, M.-L.; James, R. W. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radic. Biol. Med. 50:102-109; 2011.
36. Efrat, M.; Aviram, M. Macrophage paraoxonase 1 (PON1) binding sites. Biochem. Biophys. Res. Commun 376:105-110; 2008.
37. Efrat, M.; Rosenblat, M.; Mahmood, S.; Vaya, J.; Aviram, M. Di-oleoyl phos-phatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies. Atherosclerosis 202:461-469; 2009.
38. Vedhachalam, C.; Duong, P. T.; Nickel, M.; Nguyen, D.; Dhanasekaran, P.; Saito, H.; et al. Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J. Biol. Chem. 282:25123-25130; 2007.
39. Felton, C. V.; Crook, D.; Davies, M. J.; Oliver, M. F. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler. Thromb. Vasc. Biol. 17: 1337-1345; 1997.
40. Kadowaki, H.; Patton, G. M.; Robins, S. J. Effect of phosphatidylcholine molecular species on the uptake of HDL triglycerides and cholesteryl esters by the liver. J. Lipid Res. 34:180-189; 1993.
41. Fuhrman, B.; Gantman, A.; Aviram, M. Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against apoptosis. Atherosclerosis 211:61-68; 2010.
42. Marsillach, J.; Camps, J.; Beltran-Debón, R.; Rull, A.; Aragones, G.; Maestre-Martínez, C.; et al. Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques. Eur. J. Clin. Invest. 41:308-314; 2011.